查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1755939

2032 年感染疾病藥物市場預測：按感染疾病類型、藥物類別、給藥方式、分銷管道、最終用戶和地區進行的全球分析

Infectious Disease Therapeutics Market Forecasts to 2032 - Global Analysis By Infection Type, Drug Class, Mode of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球感染疾病藥物市場預計在 2025 年達到 1,352.5 億美元，到 2032 年將達到 2,064.9 億美元，預測期內的複合年成長率為 6.23%。

感染疾病藥物涵蓋多種旨在對抗細菌、病毒、真菌和寄生蟲感染疾病的治療方法。抗生素、抗病毒藥物、抗真菌藥物和抗寄生蟲藥物就是其中的一些例子，它們都作用於特定病原體，以根除感染或阻止其傳播。隨著抗藥性細菌和感染疾病的增多，開發創新治療方法和疫苗變得越來越重要。生物技術和分子診斷技術的發展使得更精準、更有效率的個人化治療成為可能。

根據世界衛生組織 (WHO) 預測，到 2022 年，病毒性肝炎（乙型和丙型）將超過結核病，造成 130 萬人死亡。預計到 2040 年，病毒性肝炎造成的死亡人數將超過瘧疾、結核病和愛滋病造成的年度死亡人數總合，這凸顯了對強效感染疾病物的迫切需求。

感染疾病率上升

感染疾病的流行仍然是全球最大的健康負擔之一。根據世界衛生組織估計，愛滋病毒/愛滋病、肝炎、瘧疾和結核病每年導致數百萬人死亡，尤其是在中低收入國家。由於新冠肺炎 (COVID-19) 等疫情以及流感等季節性疾病的爆發，醫療保健系統也承受著巨大的壓力。此外，這種持續且日益加重的負擔迫切需要有效的治療方法，以降低死亡率並改善患者預後。

昂貴的臨床試驗和藥物開發

開發新型感染疾病治療方法需要臨床前研究、多個階段的臨床試驗以及深入的研究和開發，所有這些都成本高且耗時。將一種藥物推向市場可能需要十多年的時間，耗資數十億美元。製藥公司不願開發主要影響低收入者的新型感染疾病治療方法。此外，監管機構嚴格的安全性和有效性要求也推高了開發成本和時間。

增加生物防禦和流行病防範支出

各國政府和國際組織正加大對衛生安全的投入，尤其注重開發應對新興感染疾病威脅的快速反應平台、提升研發能力以及累積抗病毒藥物。此外，世界衛生組織研發藍圖、美國生物醫學高級機會與發展管理局（BARDA）和流行病防範創新聯盟（CEPI）等計畫也為藥物研發人員提供了大量資金和合作機會。

病原體的快速進化和變異

細菌和病毒的適應性和快速突變有時會使現有療法失效。 Omicron 等新型 COVID-19 變種的出現表明，病原體變異速度極快，甚至超過了疫苗和治療方法的研發速度。此外，這種不可預測性也威脅長期治療效果，需要持續監測、再投資和更新治療通訊協定，這增加了製藥公司的開發風險和成本。

COVID-19的影響：

新冠疫情改變了全球衛生優先事項，增加了資金投入，並加速了技術創新，所有這些都對感染疾病治療市場產生了深遠的影響。這導致了對mRNA技術、單株抗體和抗病毒藥物的空前投資。監管機構採取了加速核准途徑，為未來藥物開發設立了新的標準，使得更快的治療部署成為可能。疫情也增強了遠端醫療和數位健康在疾病控制、促進跨境合作和提高公眾感染疾病意識方面的作用。

疫苗領域預計將成為預測期內最大的領域

預計疫苗領域將在預測期內佔據最大的市場佔有率。全球意識的不斷增強、政府對疫苗宣傳活動的廣泛支持以及免疫接種計劃的廣泛實施是疫苗佔據主導地位的主要原因。如今，疫苗不僅提供預防性保護，也已成為控制流行病和流行疾病的策略工具。疫苗在成人和兒童族群中的廣泛應用，加上mRNA和重組基因技術的不斷發展，鞏固了其市場領導地位，確保了其在已開發經濟體和新興經濟體的穩定成長。

預計預測期內鼻腔部分將以最高的複合年成長率成長。

預計鼻腔給藥領域將在預測期內達到最高成長率。這一成長可歸因於對無針非侵入性給藥技術日益成長的需求，這些技術可提高患者（尤其是年輕人和老年人）的依從性。此外，鼻腔給藥製劑無需經胃腸道和首過代謝，起效迅速，使其成為緊急治療和疫苗接種的理想選擇。抗病毒噴劑和經鼻吸入型疫苗的最新進展提升了人們對該細分市場的興趣和投資，使其成為未來成長的關鍵領域。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。該地區擁有完善的醫療體系、高昂的醫療支出以及眾多頂尖生物技術和製藥公司的強勁發展勢頭。該地區擁有強大的研發能力、廣泛的尖端治療方法，以及令人欣喜的法規環境，例如快速的FDA核准流程。此外，肝炎、愛滋病毒和流感等感染疾病的高發病率、政府資助的疫苗接種和公共衛生宣傳活動也對該地區市場佔據主導地位宣傳活動了重要作用。

複合年成長率最高的地區：

預計亞太地區在預測期內的複合年成長率最高。感染疾病率上升、醫療基礎設施建設不斷完善以及公共和私人部門對藥物開發和醫學研究的投資不斷增加是推動這一成長的主要動力。在中國、印度和東南亞等國家，人口成長和疾病意識增強，推動了對更廉價、更有效治療方法的需求。此外，該地區生物技術公司的推出、診斷技術的進步以及政府主導的疫苗接種宣傳活動正在加速治療方法的普及。該地區不斷變化的法規環境也為快速擴張的市場提供了支持。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章全球感染疾病藥物市場（依感染疾病類型）

  • 細菌感染疾病
  • 病毒感染
    • 人類免疫力缺乏病毒（HIV/AIDS）
    • B型肝炎
    • C型肝炎
    • 流感
    • HPV
  • 黴菌感染疾病
  • 寄生蟲感染疾病
  • 其他類型的感染疾病

6. 全球感染疾病藥物市場（依藥物類別）

  • 抗菌劑
  • 抗病毒藥物
  • 抗真菌藥物
  • 抗寄生蟲藥
  • 疫苗
  • 其他藥物類別

7. 全球感染疾病藥物市場（依給藥方式）

  • 口服
  • 腸外
  • 鼻內

第8章全球感染疾病藥物市場按分銷管道

  • 醫院藥房
  • 零售藥局
  • 其他分銷管道

第9章全球感染疾病藥物市場（依最終用戶）

  • 醫院和診所
  • 研究所
  • 診斷中心
  • 其他最終用戶

第10章全球感染疾病藥物市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • BioCryst Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim GmbH
  • Gilead Sciences Inc.
  • AstraZeneca Inc
  • Merck & Co., Inc.
  • Bayer AG
  • Amgen Inc.
  • Novartis AG
  • Bristol-Myers Squibb（BMS）
  • Abbott Laboratories
  • Pfizer Inc.
  • Sanofi
  • Janssen Pharmaceutical Inc.
  • Takeda Pharmaceutical
  • Sandoz International GmbH
Product Code: SMRC29833

According to Stratistics MRC, the Global Infectious Disease Therapeutics Market is accounted for $135.25 billion in 2025 and is expected to reach $206.49 billion by 2032 growing at a CAGR of 6.23% during the forecast period. Infectious disease therapeutics encompasses a broad range of treatments aimed at combating infections caused by bacteria, viruses, fungi, and parasites. Antibiotics, antivirals, antifungals, and antiparasitic medications are examples of these therapeutics; they all work against particular pathogens to eradicate or stop the spread of infection. The creation of innovative treatments and vaccines has become more and more important as drug-resistant bacteria and infectious diseases have increased. More accurate, efficient, and individualized treatments are now possible owing to developments in biotechnology and molecular diagnostics.

According to the World Health Organization, viral hepatitis (B and C) caused 1.3 million deaths in 2022, surpassing tuberculosis, and is projected to exceed the combined annual fatalities of malaria, TB, and AIDS by 2040-a stark indicator of the urgent need for potent infectious disease therapeutics.

Market Dynamics:

Driver:

Increasing infectious disease incidence

One of the biggest health burdens in the world is still the prevalence of infectious diseases. WHO estimates that HIV/AIDS, hepatitis, malaria, and tuberculosis together account for millions of deaths each year, particularly in low- and middle-income nations. Healthcare systems are also still under stress from outbreaks like COVID-19 and seasonal illnesses like influenza. Additionally, the need for efficient treatments to lower mortality and enhance patient outcomes is sustained by this ongoing and increasing burden.

Restraint:

Expensive clinical trials and drug development

Preclinical research, several stages of clinical trials, and intensive R&D are all necessary to develop new treatments for infectious diseases, and they are all costly and time-consuming. To get a single drug to market, it can take more than ten years and cost billions of dollars. Pharmaceutical companies are discouraged from pursuing new treatments for infectious diseases that primarily affect low-income populations because the return on investment may be low. Furthermore, raising development costs and timelines are regulatory bodies' strict safety and efficacy requirements.

Opportunity:

Increasing spending on biodefense and pandemic preparedness

Governments and international organizations are investing more in health security, with a particular emphasis on developing rapid-response platforms for emerging infectious threats, improving R&D capabilities, and accumulating antivirals. Moreover, drug developers can find substantial funding and collaboration opportunities through programs like WHO's R&D Blueprint, BARDA (Biomedical Advanced Research and Development Authority), and CEPI (Coalition for Epidemic Preparedness Innovations).

Threat:

Rapid pathogen evolution and mutation

Due to their high degree of adaptability and rapid mutation, bacteria and viruses can occasionally make current treatments ineffective. The appearance of novel COVID-19 variations, like Omicron, showed how quickly pathogens can change and surpass the development of vaccines and treatments. Additionally, long-term therapeutic efficacy is threatened by this unpredictability, necessitating ongoing monitoring, reinvestment, and treatment protocol updates, which raises development risks and costs for pharmaceutical companies.

Covid-19 Impact:

The COVID-19 pandemic changed the priorities of global health, boosted funding, and accelerated innovation, all of which had a substantial impact on the infectious disease therapeutics market. It highlighted the urgent need for quick therapeutic development, which resulted in previously unheard-of investments in mRNA technology, monoclonal antibodies, and antiviral medications. Faster treatment deployment was made possible by regulatory bodies' adoption of expedited approval pathways, which established a new standard for future drug development. The pandemic also increased the role of telemedicine and digital health in disease management, promoted cross-border cooperation, and raised public awareness of infectious diseases.

The vaccines segment is expected to be the largest during the forecast period

The vaccines segment is expected to account for the largest market share during the forecast period. Increased global awareness, extensive government support for vaccination campaigns, and extensive immunization programs are the main causes of this dominance. Vaccines are now a strategic tool for managing pandemics and epidemics in addition to providing preventive protection. Their widespread application in both adult and pediatric populations, combined with ongoing developments in mRNA and recombinant technologies, has strengthened their position as market leaders and guaranteed steady growth in both developed and emerging nations.

The intranasal segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the intranasal segment is predicted to witness the highest growth rate. This expansion is fueled by a growing desire, particularly among young and elderly populations, for needle-free, non-invasive drug delivery techniques that improve patient compliance. Moreover, intranasal formulations are perfect for emergency treatments and vaccinations because they provide a quick onset of action by avoiding the gastrointestinal tract and first-pass metabolism. Recent advancements in antiviral sprays and intranasal vaccines, increased interest in and investment in this market segment and established it as a crucial area for future growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, propelled by its sophisticated healthcare system, substantial healthcare expenditures, and robust presence of top biotechnology and pharmaceutical firms. The area gains from strong R&D capacities, broad use of cutting-edge treatment alternatives, and encouraging regulatory environments such as the FDA's expedited approval processes. Additionally, the high incidence of infectious diseases like hepatitis, HIV, and influenza, as well as government-sponsored immunization campaigns and public health campaigns, also play a big role in market dominance.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Rising infectious disease rates, growing healthcare infrastructure, and rising public and private investments in drug development and medical research are the main drivers of this growth. Because of their expanding populations and increased awareness of disease, countries like China, India, and Southeast Asia are seeking more affordable and efficient treatments. Furthermore, the launch of regional biotech companies, advancements in diagnostic technology and government-led vaccination campaigns are speeding up the adoption of treatments. The rapidly expanding market is further supported by the region's changing regulatory environment.

Key players in the market

Some of the key players in Infectious Disease Therapeutics Market include BioCryst Pharmaceuticals Inc. , GlaxoSmithKline plc, AbbVie Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Gilead Sciences Inc., AstraZeneca Inc, Merck & Co., Inc. , Bayer AG, Amgen Inc., Novartis AG, Bristol-Myers Squibb (BMS), Abbott Laboratories, Pfizer Inc. , Sanofi , Janssen Pharmaceutical Inc., Takeda Pharmaceutical and Sandoz International GmbH.

Key Developments:

In June 2025, BioCryst Pharmaceuticals, Inc. announced the extension of its consulting agreement with former Chief Financial Officer Anthony Doyle. This information was disclosed in a recent SEC filing. The company, with a market capitalization of $2.34 billion, has shown impressive momentum with a 66% return over the past year and revenue of $503 million in the last twelve months.

In February 2025, AbbVie and Xilio Therapeutics, Inc. announced collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology. Xilio has developed a proprietary, clinically-validated platform technology for tumor-activated biologics.

In January 2025, GSK plc has agreed to acquire IDRx, a Boston-based, clinical-stage Biopharmaceutical Company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.

Infection Types Covered:

  • Bacterial Infections
  • Viral Infections
  • Fungal Infections
  • Parasitic Infections
  • Other Infection Types

Drug Classes Covered:

  • Antibacterials
  • Antivirals
  • Antifungals
  • Antiparasitic Drugs
  • Vaccines
  • Other Drug Classes

Mode of Administrations Covered:

  • Oral
  • Parenteral
  • Intranasal

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals & Clinics
  • Research Organizations
  • Diagnostic Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Infectious Disease Therapeutics Market, By Infection Type

  • 5.1 Introduction
  • 5.2 Bacterial Infections
  • 5.3 Viral Infections
    • 5.3.1 Human Immunodeficiency Virus (HIV/AIDS)
    • 5.3.2 Hepatitis B
    • 5.3.3 Hepatitis C
    • 5.3.4 Influenza
    • 5.3.5 HPV
  • 5.4 Fungal Infections
  • 5.5 Parasitic Infections
  • 5.6 Other Infection Types

6 Global Infectious Disease Therapeutics Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antibacterials
  • 6.3 Antivirals
  • 6.4 Antifungals
  • 6.5 Antiparasitic Drugs
  • 6.6 Vaccines
  • 6.7 Other Drug Classes

7 Global Infectious Disease Therapeutics Market, By Mode of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Intranasal

8 Global Infectious Disease Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Other Distribution Channels

9 Global Infectious Disease Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Research Organizations
  • 9.4 Diagnostic Centres
  • 9.5 Other End Users

10 Global Infectious Disease Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 BioCryst Pharmaceuticals Inc.
  • 12.2 GlaxoSmithKline plc
  • 12.3 AbbVie Inc.
  • 12.4 F. Hoffmann-La Roche Ltd.
  • 12.5 Boehringer Ingelheim GmbH
  • 12.6 Gilead Sciences Inc.
  • 12.7 AstraZeneca Inc
  • 12.8 Merck & Co., Inc.
  • 12.9 Bayer AG
  • 12.10 Amgen Inc.
  • 12.11 Novartis AG
  • 12.12 Bristol-Myers Squibb (BMS)
  • 12.13 Abbott Laboratories
  • 12.14 Pfizer Inc.
  • 12.15 Sanofi
  • 12.16 Janssen Pharmaceutical Inc.
  • 12.17 Takeda Pharmaceutical
  • 12.18 Sandoz International GmbH

List of Tables

  • Table 1 Global Infectious Disease Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Infectious Disease Therapeutics Market Outlook, By Infection Type (2024-2032) ($MN)
  • Table 3 Global Infectious Disease Therapeutics Market Outlook, By Bacterial Infections (2024-2032) ($MN)
  • Table 4 Global Infectious Disease Therapeutics Market Outlook, By Viral Infections (2024-2032) ($MN)
  • Table 5 Global Infectious Disease Therapeutics Market Outlook, By Human Immunodeficiency Virus (HIV/AIDS) (2024-2032) ($MN)
  • Table 6 Global Infectious Disease Therapeutics Market Outlook, By Hepatitis B (2024-2032) ($MN)
  • Table 7 Global Infectious Disease Therapeutics Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 8 Global Infectious Disease Therapeutics Market Outlook, By Influenza (2024-2032) ($MN)
  • Table 9 Global Infectious Disease Therapeutics Market Outlook, By HPV (2024-2032) ($MN)
  • Table 10 Global Infectious Disease Therapeutics Market Outlook, By Fungal Infections (2024-2032) ($MN)
  • Table 11 Global Infectious Disease Therapeutics Market Outlook, By Parasitic Infections (2024-2032) ($MN)
  • Table 12 Global Infectious Disease Therapeutics Market Outlook, By Other Infection Types (2024-2032) ($MN)
  • Table 13 Global Infectious Disease Therapeutics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 14 Global Infectious Disease Therapeutics Market Outlook, By Antibacterials (2024-2032) ($MN)
  • Table 15 Global Infectious Disease Therapeutics Market Outlook, By Antivirals (2024-2032) ($MN)
  • Table 16 Global Infectious Disease Therapeutics Market Outlook, By Antifungals (2024-2032) ($MN)
  • Table 17 Global Infectious Disease Therapeutics Market Outlook, By Antiparasitic Drugs (2024-2032) ($MN)
  • Table 18 Global Infectious Disease Therapeutics Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 19 Global Infectious Disease Therapeutics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 20 Global Infectious Disease Therapeutics Market Outlook, By Mode of Administration (2024-2032) ($MN)
  • Table 21 Global Infectious Disease Therapeutics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 22 Global Infectious Disease Therapeutics Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 23 Global Infectious Disease Therapeutics Market Outlook, By Intranasal (2024-2032) ($MN)
  • Table 24 Global Infectious Disease Therapeutics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 25 Global Infectious Disease Therapeutics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 26 Global Infectious Disease Therapeutics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 27 Global Infectious Disease Therapeutics Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
  • Table 28 Global Infectious Disease Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global Infectious Disease Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 30 Global Infectious Disease Therapeutics Market Outlook, By Research Organizations (2024-2032) ($MN)
  • Table 31 Global Infectious Disease Therapeutics Market Outlook, By Diagnostic Centres (2024-2032) ($MN)
  • Table 32 Global Infectious Disease Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.